← Browse by Condition
Medical Condition
neovascular age related macular degeneration
Total Trials
5
Recruiting Now
5
Trial Phases
Phase 1, Phase 2, Phase 3
ClinicalMetric tracks all active clinical trials for neovascular age related macular degeneration sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.
Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.
Frequently Asked Questions — neovascular age related macular degeneration Clinical Trials
How many clinical trials are currently recruiting for neovascular age related macular degeneration?
ClinicalMetric currently tracks 5 actively recruiting clinical trials for neovascular age related macular degeneration, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 5. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for neovascular age related macular degeneration?
neovascular age related macular degeneration research spans Phase 1 (2 trials), Phase 2 (2 trials), Phase 3 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a neovascular age related macular degeneration clinical trial?
Eligibility criteria for neovascular age related macular degeneration trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 2
Phase 2 2
Phase 3 3
Top Sponsors
2 trials
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05986864 Phase 1, Phase 2
Recruiting
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
Enrollment
68 pts
Location
United States, China
Sponsor
Skyline Therapeutics (US) Inc.
NCT03683251 Phase 3
Recruiting
Extension Study for the Port Delivery System With Ranibizumab (Portal)
Enrollment
1,000 pts
Location
United States, Argen...
Sponsor
Hoffmann-La Roche
NCT07007065 Phase 3
Recruiting
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment
561 pts
Location
United States, Austr...
Sponsor
AbbVie
NCT06660667 Phase 1, Phase 2
Recruiting
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
Enrollment
66 pts
Location
United States
Sponsor
Sanofi
NCT06847542 Phase 3
Recruiting
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Enrollment
250 pts
Location
Austria, Czechia, De...
Sponsor
Hoffmann-La Roche
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology